INTRODUCTION AND OBJECTIVES: Cancer stem cells
, that closely correlated with tumor growth, metastasis and provide a plausible explanation for chemoresistance and cancer relapse. CSCs were isolated and enriched from carcinoma cells usually, which were inconvenient, low-efficient, and even unreliable. The purpose of this study was to establish prostate CSCs converted from mouse induced pluripotent stem (iPS) cells, that would allow us to monitoring tumor progression and tracking novel drug response.
METHODS: We converted mouse iPS cells into prostate CSCs with defined carcinoma microenvironment following exposure to conditioned medium (CM) derived from RM9-KLK3, a mouse prostate cancer cell line encoded by human KLK3/PSA gene. We also evaluated the expression of various stemness genes and cancer stem cell surface markers, including Oct3/4, Sox2, Nanog, Klf-4, c-Myc, CD44 and CD133, accompanied with the prostate special antigen (PSA) in these cells. In addition, in vivo transplantation experiment was performed to confirmed the tumorigenicity. Furthermore, we used these model on assess new drug response.
RESULTS: These induction CSCs expressed embryonic stem cell markers, accompanied by significantly elevated expression of CSCs surface markers and PSA. Moreover, after subcutaneous injection into C57BL/6 mice, these cells displayed high tumorigenicity. The tumor derived from CSCs exhibited malignant phenotype and showed high expression of Ki-67 and CD31. We also confirmed that novel drug, such as cancer stemness inhibitor suppressed these induction cells significantly compared to the chemotherapy (in vitro and in vivo assay). RT-PCR and Western blot analysis suggested the possible mechanism underlying this effect was dependent on suppressing cancer stemness.
CONCLUSIONS: An efficient approach to enrich CSCs is extremely important for advancing cancer research. In current study, we converted mouse iPS cells into prostate CSCs with defined carcinoma niche. It is noteworthy that these induction CSCs model displayed stemness accompanied by high tumorigenicity, which could help design better agent for cancer therapeutic and suppress cancer relapse.
Source of Funding: An efficient approach to enrich CSCs is extremely important for advancing cancer research. In current study, we converted mouse iPS cells into prostate CSCs with defined carcinoma niche. It is noteworthy that these induction CSCs model displayed stemness accompanied by high tumorigenicity, which could help design better agent for cancer therapeutic and suppress cancer relapse.
MP41-13 AMNIOTIC FLUID FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Michael Zahalsky*, Gina Dessources, Melissa Marchand, Coral Springs, FL; Jason Levy, Philadephia, PA INTRODUCTION AND OBJECTIVES: There is demand for a non-pharmaceutical approach to treating Erectile Dysfunction (ED). Proflo is Amniotic Fluid (AF) which contains various cytokines and growth factors and is believed to facilitate angiogenesis and decrease inflammation. Therefore, it may prove to be a non-pharmacologic, longterm, cost effective alternative to treat ED. To determining the effectiveness of AF as a sustainable treatment for ED METHODS: A retrospective chart review of patients injected with ProFlo AF was performed. Proflo is amniotic fluid from a FDA cleared tissue bank, Vivex. It meets all the criteria to be regulated under the Public Health Service Act section 361. It is minimally manipulated, not combined with anything, not dependent on the metabolic activity of living cells, and being used homologously, since it is from the Genitourinary System and being used on the Genitourinary system. According to FDA draft guidance, Amniotic Fluid is a nonstructural biologic product that serves a biochemical role. A Penile Doppler measuring peak systolic velocity (PSV) and the International Index of Erectile Function Questionnaire (IIEF-5) were used to assess changes in erectile function. Patients were injected with 1cc -2cc's of AF, and followed up to 6 months.
RESULTS: 35 patients were injected with ProFlo AF. 15 patients injected with AF had pre and post PSV values, 12 patients had pre and post IIEF-5 scores. The average PSV after Trimix injection before administering AF was 26.65 cm/s. After AF injection in follow up, the average PSV was 37.83 cm/s (two-tailed t-test p-value < 0.005). Similarly, an increase was observed in the IIEF score for the group. IIEF score ranged from 5 to 21.5 before the initial AF injection and were between 8 to 24 after AF injection (two-tailed t-test p-value < 0.05). Patients only complaints were of minimal bruising and pain at the injection site for 2-7 days after injections.
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